Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 14, Issue SUPPL. 1, 2000, Pages

  Giacobini, Ezio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alzheimer disease; Cholinesterase inhibitors

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; METHANESULFONYL FLUORIDE; METRIFONATE; MUSCARINIC AGENT; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; EUROPE; FUTUROLOGY; HUMAN; JAPAN; LEWY BODY; LONG TERM CARE; META ANALYSIS; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SYMPTOM; UNITED STATES;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DISEASE PROGRESSION; HUMANS; TREATMENT OUTCOME;

EID: 0034082560     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200000001-00002     Document Type: Conference Paper

References (33)

1. Anand R, Hartman R, Messina J, et al. Long-term treatment with rivastigmine continue to provide benefits for up to one year. In: Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, 1998:Abstract 18.
2. Becker E, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type. Drug Dev Res 1988;12:163-95.
3. Becker R, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991:263-96.
4. Becker R, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor for Alzheimer disease. Alzheimer Dis Assoc Disord 1996a;1:124-31.
5. Becker R, Moriearty P, Unni L, et al. Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In: Becker R, Giacobini E, eds. Alzheimer Disease: from molecular biology to therapy. Boston: Birkhäuser, 1996b: 257-66.
6. Bowen DM. Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In: Branbury report 15: biological aspects of Alzheimer's disease. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1983:219-31.
7. Cummings JL, Cyrus PA, Ruzicka BB, et al. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients. Am Acad Neurol 1998;524:004.
8. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999;281: 1401-6.
9. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 1992;32:625-32.
10. Frölich L, Dirr A, Götz E, et al. Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type. J Neural Transm 1998;105:961-73.
11. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:263-91.
12. Giacobini E, Becker R, Mcilhany M, Kumar V. Intracerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients In: Giacobini E, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988:113-22.
13. Giacobini E. Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? In: Racagni G, Brunellos N, Langer SZ, eds. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. International Academy of Biomedical Drug Research. New York: Karger, 1994:51-7.
14. Giacobini E, Cuadra G. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker R, eds. Alzheimer disease: therapeutic strategies. Boston: Birkhäuser, 1994:155-71.
15. Giacobini E. Cholinesterase inhibitors: from preclinical studies to clinical efficacy in Alzheimer disease. In: Quinn D, Balasubramanian AS, Doctor BP, et al., eds. Enzymes of the cholinesterase family. New York: Plenum Press, 1995:463-9.
16. Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker R, Giacobini E, eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996:187-204.
17. Giacobini E. Cholinesterases and cholinesterase inhibitors. Basic, preclinical and clinical aspects. London: Martin Dunitz, 2000.
18. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-34.
19. Greaney M, Marshall D, During M, et al. Ultrasensitive measurement of acetylcholine release in the conscious human hippocampus and anesthetized rat striatum using microdialysis (abstract). Soc Neurosci 1992;2:137.
20. Imbimbo BP, Lucchelli PE. A pharmacodynamic strategy to optimize the clinical response to eptastigmine In: Becker R, Giacobini E, Alzheimer disease therapeutic strategies. Boston: Birkhäuser, 1994: 223-30.
21. Inestrosa N, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-pcptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91.
22. Kishnai PS, Sullivan JA, Walter KW, et al. Cholinergic therapy for Down's syndrome. Lancet 1999;353:1064-5.
23. Krupp LB, Elkins LE, Scott SR, et al. Donepezil for the treatment of memory impairment in multiple sclerosis. Neurology 1999;52(suppl 2):Abstr. 137.
24. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of beta-amyloid precursor protein in cell lines J Neurosci Res 1994;8:777-87.
25. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neurol Rep 1995;6:633-6.
26. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
27. Relkin N, Orazem J, McRae T. The effect of concomitant donepezil and estrogen treatment on the cognitive performance of women with Alzheimer's disease. 51st Annual Meeting of the American Academy of Neurology, 1999. Abstract 50.
28. Saez-Valero J, Sberna G, Small DH. The beta-amyloid protein regulates acetylcholinesterase expression, assembly and glycosylation in cell culture, APP transgenic mice an the Alzheimer brain. The Sixth International Meeting on Cholinesterases, La Jolla, CA, 1998. Abstract 6.
29. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411.
30. Thal L, Fuld PA, Masur DM, et al. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 1983;13:491-6.
31. Tohgi H, Abe T, Hashiguchi K, et al. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett 1994;177:139-42.
32. Tune L, Brandt J, Frost JJ, et al. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand 1991;366:61-5.
33. Wimo A, Winblad B, Grafstrom M. The social consequences for families with Alzheimer disease patients: potential impact of new drug treatment. Int J Geriatr Psychiatry 1998;14:338-47.